The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Duchenne Muscular Dystrophy Drugs Market Research Report 2025

Global Duchenne Muscular Dystrophy Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1429679

No of Pages : 93

Ask Your Query

Synopsis

Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market
The global Duchenne Muscular Dystrophy Drugs market size is projected to reach US$ 8086.7 million by 2028, from US$ 1011.8 million in 2021, at a CAGR of 34.0% during 2022-2028.

Fully considering the economic change by this health crisis, Molecular-based Therapies accounting for % of the Duchenne Muscular Dystrophy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.

China Duchenne Muscular Dystrophy Drugs market size is valued at US$ million in 2021, while the North America and Europe Duchenne Muscular Dystrophy Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Duchenne Muscular Dystrophy Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Duchenne Muscular Dystrophy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Duchenne Muscular Dystrophy Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Duchenne Muscular Dystrophy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Duchenne Muscular Dystrophy Drugs market.

Global Duchenne Muscular Dystrophy Drugs Scope and Market Size
Duchenne Muscular Dystrophy Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Molecular-based Therapies
  • Steroid Therapy
  • Other

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

By Company

  • Biogen
  • Roche
  • Daiichi Sankyo
  • Pfizer
  • Cumberland Pharmaceuticals
  • Santhera Pharmaceuticals
  • Taiho Pharmaceutical
  • Teijin Pharma
  • Akashi Therapeutics
  • Sarepta Therapeutics
  • Biomarin
  • Fibrogen Inc
  • Nobelpharma Co. Ltd
  • Eloxx Pharmaceuticals
Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Molecular-based Therapies
1.2.3 Steroid Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2017-2028)
2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Region
2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2017-2022)
2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028)
2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2017-2022)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2021
3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2017-2022)
4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2017-2022)
5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.1.5 Biogen Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.2.5 Roche Recent Development
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Detail
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.3.5 Daiichi Sankyo Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.4.5 Pfizer Recent Development
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Detail
11.5.2 Cumberland Pharmaceuticals Business Overview
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.5.5 Cumberland Pharmaceuticals Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Detail
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Detail
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.7.5 Taiho Pharmaceutical Recent Development
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Detail
11.8.2 Teijin Pharma Business Overview
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.8.5 Teijin Pharma Recent Development
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Detail
11.9.2 Akashi Therapeutics Business Overview
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.9.5 Akashi Therapeutics Recent Development
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Detail
11.10.2 Sarepta Therapeutics Business Overview
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.10.5 Sarepta Therapeutics Recent Development
11.11 BioMarin
11.11.1 BioMarin Company Detail
11.11.2 BioMarin Business Overview
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.11.5 BioMarin Recent Development
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Detail
11.12.2 Fibrogen Inc Business Overview
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.12.5 Fibrogen Inc Recent Development
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Detail
11.13.2 Nobelpharma Co. Ltd Business Overview
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.13.5 Nobelpharma Co. Ltd Recent Development
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Detail
11.14.2 Eloxx Pharmaceuticals Business Overview
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.14.5 Eloxx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Molecular-based Therapies
Table 3. Key Players of Steroid Therapy
Table 4. Key Players of Other
Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2017-2022)
Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2023-2028)
Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2017-2022)
Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2017-2022)
Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2023-2028)
Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2017-2022)
Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2023-2028)
Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 42. Biogen Company Detail
Table 43. Biogen Business Overview
Table 44. Biogen Duchenne Muscular Dystrophy Drugs Product
Table 45. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 46. Biogen Recent Development
Table 47. Roche Company Detail
Table 48. Roche Business Overview
Table 49. Roche Duchenne Muscular Dystrophy Drugs Product
Table 50. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Daiichi Sankyo Company Detail
Table 53. Daiichi Sankyo Business Overview
Table 54. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
Table 55. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 56. Daiichi Sankyo Recent Development
Table 57. Pfizer Company Detail
Table 58. Pfizer Business Overview
Table 59. Pfizer Duchenne Muscular Dystrophy Drugs Product
Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Cumberland Pharmaceuticals Company Detail
Table 63. Cumberland Pharmaceuticals Business Overview
Table 64. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 65. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 66. Cumberland Pharmaceuticals Recent Development
Table 67. Santhera Pharmaceuticals Company Detail
Table 68. Santhera Pharmaceuticals Business Overview
Table 69. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 70. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 71. Santhera Pharmaceuticals Recent Development
Table 72. Taiho Pharmaceutical Company Detail
Table 73. Taiho Pharmaceutical Business Overview
Table 74. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
Table 75. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 76. Taiho Pharmaceutical Recent Development
Table 77. Teijin Pharma Company Detail
Table 78. Teijin Pharma Business Overview
Table 79. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
Table 80. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 81. Teijin Pharma Recent Development
Table 82. Akashi Therapeutics Company Detail
Table 83. Akashi Therapeutics Business Overview
Table 84. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 85. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 86. Akashi Therapeutics Recent Development
Table 87. Sarepta Therapeutics Company Detail
Table 88. Sarepta Therapeutics Business Overview
Table 89. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 90. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 91. Sarepta Therapeutics Recent Development
Table 92. BioMarin Company Detail
Table 93. BioMarin Business Overview
Table 94. BioMarin Duchenne Muscular Dystrophy DrugsProduct
Table 95. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 96. BioMarin Recent Development
Table 97. Fibrogen Inc Company Detail
Table 98. Fibrogen Inc Business Overview
Table 99. Fibrogen Inc Duchenne Muscular Dystrophy DrugsProduct
Table 100. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 101. Fibrogen Inc Recent Development
Table 102. Nobelpharma Co. Ltd Company Detail
Table 103. Nobelpharma Co. Ltd Business Overview
Table 104. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy DrugsProduct
Table 105. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 106. Nobelpharma Co. Ltd Recent Development
Table 107. Eloxx Pharmaceuticals Company Detail
Table 108. Eloxx Pharmaceuticals Business Overview
Table 109. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy DrugsProduct
Table 110. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 111. Eloxx Pharmaceuticals Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2021 VS 2028
Figure 2. Molecular-based Therapies Features
Figure 3. Steroid Therapy Features
Figure 4. Other Features
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application in 2021 & 2028
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2021 VS 2028
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2021
Figure 14. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2021
Figure 16. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
Figure 18. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
Figure 22. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2017-2028)
Figure 30. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
Figure 38. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2017-2028)
Figure 42. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 45. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 46. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 47. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 48. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 49. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 50. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 51. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 52. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 53. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 54. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 55. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 56. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 57. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock